Stay updated with breaking news from Sheldonl Koenig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Equities researchers at Northland Capmk increased their FY2023 earnings estimates for Esperion Therapeutics in a research report issued on Tuesday, August 1st. Northland Capmk analyst C. Byrnes now expects that the biopharmaceutical company will earn ($1.98) per share for the year, up from their previous estimate of […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at HC Wainwright upped their Q3 2023 earnings estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, August 1st. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will earn ($0.37) per share for the quarter, up from their […]
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15, Briefing.com reports. The business had revenue of $25.79 million for the quarter, compared to analyst estimates of $24.64 million. The company’s quarterly revenue was […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at Zacks Research decreased their Q2 2023 earnings estimates for shares of Esperion Therapeutics in a research report issued on Thursday, July 27th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of ($0.64) per share for the quarter, down […]
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by equities research analysts at Northland Securities from an “underperform” rating to a “market perform” rating in a report issued on Tuesday, MarketBeat reports. ESPR has been the subject of several other reports. Bank of America upgraded shares of Esperion Therapeutics from an “underperform” rating to […]